文献速递妇科

晚期宫颈癌患者的治疗模式与医疗费用趋势

Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
PubMed 文献 · Gynecol Oncol · 2022-01-12

基于美国商业保险理赔数据库的回顾性分析,纳入2015年至2020年第一季度1323例复发性或转移性宫颈癌女性,评估各线治疗的模式、疗程及总医疗费用。结果显示二线及以上无明确标准方案,帕博利珠单抗2018年获批后二线免疫治疗使用增加,但仅少数患者长期使用;二线月均费用最高。

要点

  • 1323例复发性或转移性宫颈癌女性中,438例接受二线治疗,其中129例接受三线治疗。
  • 帕博利珠单抗2018年获批后,二线免疫治疗使用从2015年的0%升至2019年/2020年第一季度的37%。
  • 二线治疗月均总费用最高,为77661美元,主要由门诊费用驱动。

核心结论

  • 二线及以上治疗未观察到明确的标准治疗方案。
  • 尽管免疫治疗在二线及以上治疗中使用增加,但仅小部分患者长期使用免疫治疗,提示需要更多治疗选择。

研究设计与样本

  • 美国商业保险理赔数据库的回顾性分析,纳入2015年至2020年第一季度复发性或转移性宫颈癌成年患者。
  • 一线治疗定义为首次接受全身治疗且不伴同步放化疗或手术。
  • 共1323例女性启动一线治疗,平均年龄56.1岁,平均随访16.5个月。

主要发现

  • 438例(约占三分之一)有证据接受二线治疗,其中129例(29%)有证据接受三线治疗。
  • 二线及以上治疗中无任一方案占多数。
  • 帕博利珠单抗2018年获批后,二线免疫治疗使用率从2015年的0%升至2019年/2020年第一季度的37%。
  • 每患者每月治疗期间总费用:一线47387美元,二线77661美元,三线53609美元,主要由门诊费用驱动。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current treatments for recurrent or metastatic cervical cancer (r/mCC) do not offer satisfactory clinical benefits, with most patients progressing beyond first-line (1L) treatment. With new treatments under investigation, understanding current treatment patterns, the impact of newly approved therapies, and total costs of care for r/mCC are important. METHODS: A retrospective analysis of a US commercial insurance claims database to identify adult patients with r/mCC between 2015 and Q1-2020; defining 1L treatment as the first administration of systemic treatment without concomitant chemoradiation or surgery. Patient characteristics, treatment regimens, duration of therapy, and total costs of care were evaluated for each line of therapy. RESULTS: 1323 women initiated 1L treatment for r/mCC (mean age, 56.1 years; mean follow-up, 16.5 months). One-third (n = 438) had evidence of second-line (2L) treatment; of these, 129 (29%) had evidence of third-line (3L) treatment. No regimen represented a majority among 2L+ treatments. The 2018 approval of pembrolizumab led to increased 2L immunotherapy use (0% in 2015, 37% in 2019/Q1-2020). However, only a small proportion of patients stayed on immunotherapy for a prolonged period. Mean per-patient-per-month total costs of care during treatment were $47,387 (1L), $77,661 (2L), and $53,609 (3L), driven primarily by outpatient costs. CONCLUSIONS: No clear standard of care was observed in 2L+. Although immunotherapy is increasingly used in 2L+, only a small subset of patients stayed on immunotherapy for a prolonged period, suggesting a need for more therapeutic options. Better understanding of disease biology and the introduction of new therapies may address these unmet needs.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Musa FB, Brouwer E, Ting J, et al. Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer. Gynecol Oncol. 2022. PMID: 35031189. doi:10.1016/j.ygyno.2021.12.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。